B細胞枯渇 – Medxy AI

$Early B-Cell Depletion Patterns Predict Long-Term Rituximab Outcomes and Refractory Disease in Rheumatoid Arthritis$

Early B-Cell Depletion Patterns Predict Long-Term Rituximab Outcomes and Refractory Disease in Rheumatoid Arthritis

By MedXY 08/20/2026

High-sensitivity flow cytometry reveals that early plasmablast depletion predicts 5-year rituximab response in rheumatoid arthritis, while incomplete memory B-cell depletion signals poly-refractory disease.

Neurology news

Comparative Effectiveness and Safety of Emerging Myasthenia Gravis Therapies: Insights From a Bayesian Network Meta-Analysis

By MedXY 07/20/2026

A Bayesian network meta-analysis comparing FcRn inhibitors, C5 complement inhibitors, and CD19+ B-cell depletion therapies reveals comparable efficacy but varied safety profiles in generalized myasthenia gravis treatment, highlighting the need for prospective head-to-head trials.

Hematology-Oncology Internal Medicine news

Revolutionizing iTTP Treatment: Reverse CAR T Cells Target Autoreactive B Cells with Precision

By MedXY 04/24/2026

A groundbreaking study introduces reverse CAR T cells to selectively deplete anti-ADAMTS13 autoreactive B cells in immune-mediated thrombotic thrombocytopenic purpura (iTTP), offering a novel, precise, and potentially safer therapeutic approach.